Key Points
- Hanlin Gao sold 1,673 Fulgent Genetics shares at an average price of $19.66, generating $32,891.18. The sale covered tax-withholding obligations, and Gao retained 986,117 shares afterward.
- Fulgent Genetics recently reported weaker-than-expected quarterly results, with an adjusted loss of $0.58 per share versus the $0.46 consensus estimate and revenue of $85.39 million versus $94 million expected.
- Analyst sentiment remains cautious: the stock has an overall “Hold” rating and an average price target of $27.50, while institutional investors own approximately 48.06% of the company.
Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) insider Hanlin Gao sold 1,673 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total transaction of $32,891.18. Following the transaction, the insider directly owned 986,117 shares of the company's stock, valued at approximately $19,387,060.22. This represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Hanlin Gao also recently made the following trade(s):
- On Thursday, August 27th, Hanlin Gao sold 939 shares of Fulgent Genetics stock. The shares were sold at an average price of $19.91, for a total value of $18,695.49.
Fulgent Genetics Price Performance
Shares of FLGT opened at $19.65 on Friday. The business's fifty day moving average price is $19.71 and its 200 day moving average price is $18.01. Fulgent Genetics, Inc. has a 12-month low of $13.46 and a 12-month high of $31.04. The stock has a market capitalization of $540.57 million, a PE ratio of -6.97 and a beta of 0.93.
Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.The business had revenue of $85.39 million for the quarter, compared to analyst estimates of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350--2.220 EPS. As a group, research analysts anticipate that Fulgent Genetics, Inc. will post -3.48 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on FLGT. Wall Street Zen raised Fulgent Genetics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 29th. Piper Sandler increased their target price on Fulgent Genetics from $15.00 to $19.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings upgraded Fulgent Genetics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 27th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $27.50.
View Our Latest Stock Analysis on FLGT
Institutional Investors Weigh In On Fulgent Genetics
A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Fulgent Genetics during the second quarter worth approximately $46,922,000. Northwestern Mutual Wealth Management Co. grew its holdings in Fulgent Genetics by 2,984,354.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company's stock worth $39,985,000 after buying an additional 1,522,021 shares in the last quarter. RTW Investments LP acquired a new stake in Fulgent Genetics in the 4th quarter valued at approximately $18,521,000. JPMorgan Chase & Co. increased its position in Fulgent Genetics by 767.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company's stock valued at $6,758,000 after acquiring an additional 264,524 shares during the period. Finally, Medina Value Partners LLC bought a new stake in Fulgent Genetics during the 2nd quarter valued at $3,961,612. Institutional investors own 48.06% of the company's stock.
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company's infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.
Fulgent's product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
